FERMT2 and prostate cancer: Mechanistically, we found miR-138 to specifically target and inhibit kindlin-2 in prostate cancer cell lines, which resulted in dysregulation of the kindlin-2/β1-integrin pathway, thereby identifying a novel miR-138/kindlin-2/β1-integrin signaling axis that is critical for the modulation of sensitivity to chemotherapeutics.